Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 8/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503291 | 0.92 | KMT2A (0.45) | KMT2AMEN1RAB9ANPC1ALOX12 | |
| SCHEMBL5338964 | 0.92 | KMT2A (0.45) | KMT2AMEN1RAB9ANPC1ALOX12 | |
| SCHEMBL4507577 | 0.90 | RAB9A (0.52) | KMT2AMEN1RAB9ANPC1ALOX12 | |
| SCHEMBL4238041 | 0.89 | RAB9A (0.42) | KMT2AMEN1RAB9ANPC1ALOX12 | |
| SCHEMBL4499595 | 0.86 | KDR (0.38) | HRH3 | |
| SCHEMBL4516481 | 0.84 | MET (0.39) | P2RX3 | |
| SCHEMBL5339765 | 0.84 | MET (0.39) | P2RX3 | |
| SCHEMBL4238022 | 0.84 | KMT2A (0.41) | KMT2AMEN1RAB9ANPC1ALOX12 | |
| SCHEMBL5333924 | 0.82 | HSPB1 (0.37) | KMT2ARAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL4497632 | 0.82 | HSPB1 (0.37) | KMT2ARAB9ANPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | claimed |
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-08-13 | — | — | US | disclosed |
| WO-2007029062-A2 | NOVEL PYRIDINE DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203744-A1 | NOVEL PYRIDINE DERIVATIVES | CYP3A4, CYP4B1, CYP3A5 | KMT2A 3422/4885MEN1 1665/4885RAB9A 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.